Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00201955 · ClinicalTrials.gov registry record · Phase 3
Study of Rebamipide Eye Drops to Treat Dry Eye
A Phase 3 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 3
- Development phase
- 762
- Enrollment target
NCT00201955 is a Phase 3 study that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 762 participants.
The verdict
NCT00201955, a Phase 3 study, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 762 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the potential safety and effectiveness of rebamipide eye drops, an investigational eye drop being developed for the treatment of keratoconjunctivitis sicca (dry eye).
Interventions
- DRUG Placebo
- DRUG Rebamipide 1%
- DRUG Rebamipide 2%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 762 participants |
| Start Date | 2004-05-01 |
| Est. Completion | 2006-07-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00201955
The ClinicalTrials.gov registry entry for NCT00201955 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 762 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00201955 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00201955 about?
NCT00201955 is a clinical study titled "Study of Rebamipide Eye Drops to Treat Dry Eye". The purpose of this study is to determine the potential safety and effectiveness of rebamipide eye drops, an investigational eye drop being developed for the treatment of keratoconjunctivitis sicca (dry eye).
What is the current status of trial NCT00201955?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 762 participants. The study started on 2004-05-01. Estimated completion is 2006-07-01.
What interventions are being tested in trial NCT00201955?
The interventions under investigation include: Placebo (DRUG), Rebamipide 1% (DRUG), Rebamipide 2% (DRUG).
Who is sponsoring clinical trial NCT00201955?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.